TORONTO, April 8 /CNW/ - GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has appointed Dr. David Sable to the GeneNews Board of Directors. Dr. Sable directs all life sciences investing for the Special Situations Funds based in New York.
"Special Situations is a leader amongst U.S. life sciences funds and one of our core investors. Dr. Sable brings a deep knowledge of the challenges and opportunities facing companies in the biotech and diagnostic space and has broad relationships across the industry," said Rory Riggs, Chair of the GeneNews Board of Directors. "This expertise, in addition to Dr. Sable's experience in clinical medicine will provide GeneNews with valuable insights as we continue with the roll out of our ColonSentry(TM) test and look forward to the development and commercialization of additional groundbreaking tests based on our Sentinel Principle(TM) platform technology. We are very pleased to welcome Dr. Sable to our team."
"GeneNews is an emerging company that is just ramping up the commercialization of its first product, the ColonSentry(TM) test," said Dr. David Sable. "This innovative blood test can potentially save lives and provide a cost effective solution for avoiding the expensive healthcare claims related to late stage colorectal cancer. I look forward to working with the management and Board of GeneNews as they continue with the commercialization of ColonSentry and development of additional tests in their Sentry pipeline."
Dr. Sable served as resident and chief resident in obstetrics and gynecology at New York Hospital-Cornell Medical Center and as fellow in reproductive endocrinology at the Brigham and Women's Hospital in Boston. He was also director of the Institute for Reproductive Medicine and Science at Saint Barnabas Medical Center in New Jersey and managed a proprietary healthcare portfolio at Deutsche Bank. Dr. Sable is a graduate of the Wharton School and the University Of Pennsylvania School Of Medicine.
GeneNews is focused on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(TM) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. ColonSentry is the world's first blood test for colorectal cancer screening and the first product in the GeneNews' Sentry line of products. For more information on GeneNews, visit www.genenews.com.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.
SOURCE GeneNews Limited
For further information: For further information: Casey Gurfinkel, (416) 815-0700 x 283, email@example.com